Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-609 | Hunter Syndrome | NDA Filing | Ongoing | Intrathecal | Genetic Disorder |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Soticlestat (TAK-935/OV935)- (Skyline) | Dravet Syndrome / Lennox-Gastaut Syndrome | Phase 3 | Data Released | Oral | Neurology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Soticlestat (TAK-935/OV935)- (Skyline) | Dravet Syndrome / Lennox-Gastaut Syndrome | Phase 3 | Data Released | Oral | Neurology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Elritercept (KER-050) | Myelodysplastic syndromes (MDS) | Phase 3 | Trial Planned | Subcutaneous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Modakafusp alfa (TAK-573) | Relapsed/Refractory Multiple Myeloma | Phase 3 | Trial Planned | Intravenous | Oncology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Pevonedistat-3001 - (PANTHER) | Higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) | Phase 3 | Trial Discontinued | Intravenous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Ixazomib - (TOURMALINE-MM4) | Multiple myeloma | Phase 3 | Trial Discontinued | Oral | Oncology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | NINLARO (ixazomib) lenalidomide and dexamethasone - TOURMALINE-MM2 | Multiple myeloma | Phase 3 | Trial Discontinued | Oral | Oncology |
